Rozanski A, Berman D S
Semin Nucl Med. 1987 Apr;17(2):104-20. doi: 10.1016/s0001-2998(87)80016-8.
Radionuclide stress tests were initially introduced into medicine as new diagnostic tests for coronary artery disease (CAD). These tests are very effective for this purpose when applied to populations with an intermediate pre-test probability of coronary artery disease. Radionuclide stress tests, however, also are used now in guiding many management decisions in patients with established CAD, based on the ability of these tests to assess the extent and severity of myocardial ischemia, the functional significance of coronary stenoses, and myocardial viability. Specific uses beyond diagnosis include decisions regarding whom to catheterize, send to coronary bypass surgery, or angioplasty; risk stratification following myocardial infarction or before noncardiac surgery; and evaluation of the results of therapy. This article reviews both the diagnostic efficacy of radionuclide stress tests and their efficacy in guiding management decisions in patients with known coronary artery disease.
放射性核素负荷试验最初作为冠状动脉疾病(CAD)的新型诊断试验被引入医学领域。当应用于冠状动脉疾病预检概率处于中等水平的人群时,这些试验在这方面非常有效。然而,基于这些试验评估心肌缺血的范围和严重程度、冠状动脉狭窄的功能意义以及心肌存活性的能力,放射性核素负荷试验现在也被用于指导已确诊CAD患者的许多管理决策。除诊断之外的具体用途包括决定哪些患者需要进行心导管检查、接受冠状动脉搭桥手术或血管成形术;心肌梗死后或非心脏手术前的风险分层;以及评估治疗效果。本文综述了放射性核素负荷试验的诊断效能及其在指导已知冠状动脉疾病患者管理决策方面的效能。